Biochem/physiol Actions

Primary TargetFas/FasL-mediated cellular apoptotic signals

Cell permeable: no

Reversible: no

Product does not compete with ATP.

Kd = 11.2 & 13.2 µM for FasL and Fas (CD95/APO-1), respectively

General description

An exocyclic cysteine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (K_d = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR.

An exocyclic cystine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (K_d = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling pathways. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR.

Legal Information

Sold under license of U.S. Patent 7,288,519.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Carmona, E.M., et al. 2006. J. Immunol.177, 459.Hasegawa, A., et al. 2004. Proc. Natl. Acad. Sci. USA101, 6599.

Packaging

Packaged under inert gas

25 mg in Plastic ampoule

Physical form

Supplied as a trifluoroacetate salt.

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Sequence

H₂N-Tyr-Cys*-Asp-Glu-His-Phe-Cys*-Tyr-CO₂H, Cyclic [disulfide bond between Cys-Cys]

Warning

Toxicity: Standard Handling (A)